
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Title Sr. Director, Corporate Compliance
Reports to Chief Legal and Compliance Officer
Location Emeryville, CA (Hybrid) or west coast remote
The Sr. Director, Corporate Compliance is responsible for developing and leading the company's enterprise compliance program as the organization transitions from clinical to commercial stage. This role establishes the vision, strategy, governance, and operations of a scalable, risk-based compliance program that supports responsible business growth, commercial readiness, and a culture of ethics and integrity.
As a strategic leader and player-coach, the Sr. Director, Corporate Compliance provides enterprise-wide compliance leadership while remaining actively engaged in building and executing the program. Serving as a key member of the Legal leadership team, this role partners with executive leaders and cross-functional stakeholders to integrate compliance into the corporate strategy and business operations, proactively manage regulatory and ethical risk, and build the foundation for a high-performing Compliance function as the organization grows and transition into commercial stage.
Lead the development and ongoing effectiveness of the company's compliance program by:
The National salary range for this position is $265K to $285K USD annually. The San Francisco bay area salary range for this position is $275K-$295K This salary range is an estimate of what we reasonably expect to pay for this position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data. This position is also eligible for bonus, benefits, and participation in Company’s stock plan.

Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna’s pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.